Thus, this study investigated the MARK4 inhibitory potential of GLT as the MARK4 is associated with pathological phosphorylations of the tau protein, which further contributes to AD progression (Noble et al., 2013). The gene discussed is MAPT; the disease is Alzheimer disease.